Browsing Tag
Pfizer Inc.
22 posts
IP Group (LSE: IPO) rejects Railpen proposal worth up to 82.6p as valuation clash deepens
IP Group has rejected Railpen’s revised proposal despite a potential maximum value of 82.6 pence per share, arguing that the structure undervalues its portfolio and gives the proposed pension-fund consortium most of the future upside from Pfizer’s obesity-drug programmes.
Pfizer (PFE) tests investor patience as berobenatide moves toward Phase 3 obesity trials
Find out how Pfizer’s berobenatide data could reshape its obesity drug strategy, GLP-1 competition and investor sentiment today!
Arvinas wins first FDA-approved PROTAC as ARVN stock tests investor patience
PROTAC drugs finally have FDA validation. Arvinas now faces the harder question: can VEPPANU become a commercial oncology asset?
Intel and NVIDIA still lead—but here’s what’s driving volume in lesser-known small caps
Find out which U.S. stocks led January 27 trading by volume, and what the price action says about investor sentiment and sector trends today.
GSK reshapes ViiV Healthcare ownership as Shionogi replaces Pfizer with $2.1bn investment
Pfizer exits ViiV Healthcare as Shionogi boosts its stake to 21.7%. Find out how GSK is reshaping HIV strategy with a streamlined ownership structure.
PADCEV plus Keytruda shows survival benefit in muscle-invasive bladder cancer regardless of cisplatin eligibility
PADCEV plus Keytruda shows significant survival benefit in cisplatin-eligible muscle-invasive bladder cancer. Find out what the EV-304 data means for treatment standards.
Pfizer sweetens Metsera acquisition offer to secure board approval and fend off Novo Nordisk challenge
Find out how Pfizer’s amended $86.25-per-share merger with Metsera reshapes the obesity-drug race and signals Big Pharma’s shifting acquisition strategy.
Metsera picked Pfizer over Novo Nordisk — here’s what swung the $10bn deal
Pfizer secures obesity biotech Metsera for $10 billion after regulatory pushback sidelines Novo Nordisk. Find out what this means for pharma M&A now.
Pfizer Q3 2025 earnings beat forecasts as non-COVID drug sales lift margins and EPS guidance
Find out how Pfizer beat Q3 2025 earnings forecasts and raised full-year EPS guidance as non-COVID drugs and cost savings drove profit growth.
Merger war explodes: Pfizer drags Metsera and Novo Nordisk to court over ‘illegal’ bid
Pfizer takes legal action against Metsera and Novo Nordisk over breach of merger terms. Find out how this battle could reshape obesity drug M&A.